Supernus Pharmaceuticals SUPN
$28.61 +$0.26 (+0.92%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $28.00 -2.13%
Open$28.39
Prev close$28.35
Day range$28.15 – $29.51
Volume2.83M
Market cap$5.94B
P/E (TTM)–
Dividend yield–
SUPN Stock News
Headlines matching Supernus or the SUPN ticker, most recent first.
- Supernus Pharmaceuticals: Supernus Pharmaceuticals, Inc. - Anticipated Adjustment Option Symbol: SUPN New Symbol: SUPN1
- TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $65
- Earnings Flash (SUPN) Supernus Pharmaceuticals Posts Q2 Net Loss $1.01 a Share, Vs. FactSet Est of $0.04 EPS Negative
- Earnings Flash (SUPN) Supernus Pharmaceuticals, Inc. Reports Q2 Revenue $219.1M, Vs. FactSet Est of $205.3M
- Cantor Fitzgerald Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $67 Positive
- Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $66
- BofA Securities Initiates Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Announces Target Price $63
- Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $55
- Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $66 Positive
- TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $65 Positive
- BofA Securities Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $65
- Piper Sandler Maintains Supernus(SUPN.US) With Buy Rating, Cuts Target Price to $47 Negative
- Stifel Maintains Supernus(SUPN.US) With Hold Rating, Cuts Target Price to $37 Negative
- Cantor Fitzgerald Maintains Supernus(SUPN.US) With Buy Rating, Raises Target Price to $87 Positive
- News On Indivior Pharmaceuticals Inc. (INDV) Now Under SUPN
No comments yet — be the first to weigh in on SUPN.
Sign in to join the discussion.